| Literature DB >> 28511681 |
Liang Zhou1,2,3, Qi Ding1,2,4, Guo-Zhen Jiang1,2,3, Zhen-Ning Liu1,2,3, Hai-Yan Wang1,2,5, Guang-Rong Zhao6,7,8.
Abstract
BACKGROUND: Salvianic acid A (SAA), a valuable natural product from herbal plant Salvia miltiorrhiza, exhibits excellent antioxidant activities on food industries and efficacious therapeutic potential on cardiovascular diseases. Recently, production of SAA in engineered Escherichia coli was established via the artificial biosynthetic pathway of SAA on the multiple plasmids in our previous work. However, the plasmid-mediated system required to supplement expensive inducers and antibiotics during the fermentation process, restricting scale-up production of SAA. Microbial cell factory would be an attractive approach for constitutive production of SAA by chromosome engineering.Entities:
Keywords: Chromosomal engineering; Constitutive promoter; Escherichia coli; Metabolic engineering; Salvianic acid A; Synthetic biology
Mesh:
Substances:
Year: 2017 PMID: 28511681 PMCID: PMC5434548 DOI: 10.1186/s12934-017-0700-2
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Chromosomal engineering for constitutive production of salvianic acid A (SAA) in E. coli. a The artificial synthetic pathway of SAA from glucose. b The targeted integration of three modules into chromosome of engineered strains. In-frame deletion of the ptsG, pykF, pykA, pheA and tyrR genes were not shown in chromosome of strain BAK5. 6‐P‐G 6‐phosphate‐glucose, 6‐P‐F 6‐phosphate‐fructose, E4P erythrose‐4‐phosphate, PEP phosphoenolpyruvate, PYR pyruvic acid, DAHP 3‐deoxy‐d‐arabino‐heptulosonate‐7‐phosphate, DHS 3‐dehydroshikimic acid, SHK shikimic acid, CHA chorismic acid, -Phe l-phenylalanine, 4‐HPP 4‐hydroxyphenylpyruvic acid, -Tyr l-tyrosine, DHPP 3,4-Dihydroxyphenylpyruvate, 4-HPL 4-Hydroxyphenyllactate, TyrR-tyr TyrR-tyrosine DNA-binding transcriptional repressor, SAA salvianic acid A
Plasmids used in this study
| Plasmids | Characteristics | Source |
|---|---|---|
| pKD3 | FRT (FLP recognition target) sites; CmR | [ |
| pKD46 | Red recombinase expression vector; AmpR | [ |
| pCP20 | FLP expression vector; AmpR, CmR | [ |
| pACYCDuet-1 | p15A ori; CmR | Novagen |
| pYBT5 | pBldgbrick 1 with P | [ |
| pYBD4 | pCDFDuet-1 with | [ |
| pZL | p15A ori; CmR | This study |
| pZL1 | pZL with fragment 1 | This study |
| pZL2 | pZL with fragment 2 | This study |
| pZL3 | pZL with P | This study |
| pZL4 | pZL with P | This study |
| pZL5 | pZL with P | This study |
| pZL6 | pZL with P | This study |
| pZL7 | pZL with fragment 3 | This study |
| pZL8 | pZL7 with | This study |
| pZL9 | pZL with P | This study |
| pZL10 | pZL with P | This study |
Strains used in this study
| Strains | Characteristics | Source |
|---|---|---|
| BAK5 | BW25113 Δ | [ |
| BAK10-1 | BAK5 Δ | This study |
| BAK10 | BAK5 Δ | This study |
| BAK11-1 | BAK10 Δ | This study |
| BAK11 | BAK10 Δ | This study |
| BKD5 | BAK5 with pYBH1, pYBT5 and pYBD4 | [ |
| BKD7 | BAK11 with pZL3 | This study |
| BKD8 | BAK11 with pZL5 | This study |
| BKD9 | BAK11 with pZL6 | This study |
| BKD10 | BAK11 with pZL4 | This study |
| BKD11 | BAK11 with pZL10 | This study |
| BKD12 | BAK11 with pZL9 | This study |
| BKD13-1 | BAK11 | This study |
| BKD13 | BAK11 | This study |
Fig. 2Construction of plasmid-free chassis strain BAK11 to produce l-tyrosine constitutively. a Replacement of the mao-paa cluster with module 1. Lane 1 The paaZ gene of the mao-paa cluster in strain BAK5 with primers paaZ F/R; lane 2 ydbL-M1-Chl-ydbA fragment in strain BAK10-1 with primers ydbL F and ydbA R; lane 3 ydbL-M1-ydbA fragment in strain BAK10 with primers ydbL F and ydbA R; M: DNA marker. b Cell growth and l-tyrosine production of strains BAK5 and BAK10. 0.1 mM IPTG was added into the medium when needed. c Replacement of the lacI gene with module 2. Lane 1 ydbL-lacI-ydbA in strain BAK10; lane 2 ydbL-M2-Chl-ydbA fragment in strain BAK11-1; lane 3 ydbL-M2-ydbA fragment in strain BAK11; primers lacZ F and mhpR R were used for all PCR verification. M: DNA marker. d Cell growth and l-tyrosine production of strain BAK11. 0.1 mM IPTG was added into the medium when needed
Fig. 3Screening optimal promoter for constitutive expression of hpaBC and d-ldh for production of SAA. a The hpaBC and d-ldh were expressed as bicistron under the control of the tac and BBa-J23100 promoters. b hpaBC-d-ldh was expressed as one operon under the control of the 5tacs and rrnB P1 promoters, respectively
Fig. 4Construction of plasmid-free and inducer-free strain BKD13 for constitutive production of SAA. a Integration of module 3 into the locus between nupG and speC. Lane 1 nupG-speC fragment in strain BAK10; lane 2 nupG-M3-Chl-speC fragment in strain BAK11-1; lane 3 nupG-M3-speC fragment in strain BAK11; primers nupG F and speC R were used for all PCR verification. M: DNA marker. b The OD600 and titer of BKD13 with different initial glucose concentration. c Fed‐batch fermentation of BKD13 with glucose in shake flasks
Fig. 5Fed‐batch fermentation of BKD13 with glucose in 5 L bioreactor